1 40 1 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1517/14712598.2010.487061" target="_blank" rel="noreferrer noopener">http://doi.org/10.1517/14712598.2010.487061</a> Pages 1105–1112 Issue 7 Volume 10 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. Publisher An entity responsible for making the resource available Expert opinion on biological therapy Date A point or period of time associated with an event in the lifecycle of the resource 2010 2010-07 Subject The topic of the resource Humans; Treatment Outcome; Severity of Illness Index; Risk Assessment; Evidence-Based Medicine; Patient Selection; Ustekinumab; Antibodies; Anti-Inflammatory Agents/adverse effects/*therapeutic use; Etanercept; Immunoglobulin G/adverse effects/*therapeutic use; Immunosuppressive Agents/adverse effects/*therapeutic use; Psoriasis/*drug therapy/immunology; Receptors; Humanized; Monoclonal; Monoclonal/adverse effects/*therapeutic use; Tumor Necrosis Factor/*therapeutic use Creator An entity primarily responsible for making the resource Uhlenhake Elizabeth E; Feldman Steven R Description An account of the resource IMPORTANCE OF THE FIELD: TNF-alpha inhibitors such as etanercept have been used for psoriasis for years. A fairly well defined efficacy and safety profile has developed. A new biologic agent, ustekinumab, an IL-12 and IL-23 inhibitor, has recently been released in the US for the treatment of moderate-to-severe psoriasis. The purpose of this article is to compare the efficacy and safety profiles of ustekinumab and etanercept. AREAS COVERED IN THIS REVIEW: We examined safety and efficacy data regarding ustekinumab and etanercept from clinical reports, a head-to-head trial, review articles, and databases and registries from the last 20 years. WHAT THE READER WILL GAIN: Evidence is reviewed about the efficacy for the treatment of psoriasis as well as the safety profiles for both agents, ustekinumab and etanercept. TAKE HOME MESSAGE: Both drugs have data to confirm efficacy and safety in patients with moderate-to-severe psoriasis in the short-term. The limited long-term data on the safety profile of ustekinumab requires careful judgment on the clinician's part, weighing well-defined benefits and potential unknown risks. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1517/14712598.2010.487061" target="_blank" rel="noreferrer noopener">10.1517/14712598.2010.487061</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2010 Anti-Inflammatory Agents/adverse effects/*therapeutic use Antibodies Etanercept Evidence-Based Medicine Expert opinion on biological therapy Feldman Steven R Humanized Humans Immunoglobulin G/adverse effects/*therapeutic use Immunosuppressive Agents/adverse effects/*therapeutic use Monoclonal Monoclonal/adverse effects/*therapeutic use Patient Selection Psoriasis/*drug therapy/immunology Receptors Risk Assessment Severity of Illness Index Treatment Outcome Tumor Necrosis Factor/*therapeutic use Uhlenhake Elizabeth E Ustekinumab